OA10198A - Stable copper(i) complexes and methods related thereto - Google Patents

Stable copper(i) complexes and methods related thereto Download PDF

Info

Publication number
OA10198A
OA10198A OA60750A OA60750A OA10198A OA 10198 A OA10198 A OA 10198A OA 60750 A OA60750 A OA 60750A OA 60750 A OA60750 A OA 60750A OA 10198 A OA10198 A OA 10198A
Authority
OA
OAPI
Prior art keywords
copper
complex
complexes
stable
bcds
Prior art date
Application number
OA60750A
Other languages
English (en)
Inventor
Alexander J Pallenberg
Andrew Branca
Thomas M Marschner
Leonard M Patt
Original Assignee
Procyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procyte Corp filed Critical Procyte Corp
Publication of OA10198A publication Critical patent/OA10198A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA60750A 1993-06-02 1995-12-01 Stable copper(i) complexes and methods related thereto OA10198A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7144093A 1993-06-02 1993-06-02

Publications (1)

Publication Number Publication Date
OA10198A true OA10198A (en) 1996-12-18

Family

ID=22101339

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60750A OA10198A (en) 1993-06-02 1995-12-01 Stable copper(i) complexes and methods related thereto

Country Status (8)

Country Link
EP (1) EP0701439A1 (xx)
JP (1) JPH08511006A (xx)
AU (1) AU7051794A (xx)
CA (1) CA2163640A1 (xx)
OA (1) OA10198A (xx)
TW (1) TW239077B (xx)
WO (1) WO1994027594A2 (xx)
ZA (1) ZA943857B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
WO1996039144A1 (en) * 1995-06-06 1996-12-12 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
JP2008500347A (ja) * 2004-05-24 2008-01-10 ニュー・ヨーク・ユニヴァーシティー 高血糖症による血糖の急激な増加及び／又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法
ES2396719T3 (es) * 2005-06-20 2013-02-25 Dynamiclear Pty Ltd Composición para tratamiento de lesiones en la piel
CN102196812B (zh) * 2008-09-03 2013-11-06 株式会社Nbc纱网技术 抗病毒剂
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
TWI580787B (zh) * 2012-12-28 2017-05-01 簡宏堅 重組蛋白質、含有該重組蛋白質之醫藥組成物及該重組蛋白質之製備方法
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
US20210213021A1 (en) * 2018-06-04 2021-07-15 Lars BRICHTA Topical compositions for stimulating hair growth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤

Also Published As

Publication number Publication date
CA2163640A1 (en) 1994-12-08
WO1994027594A3 (en) 1995-04-27
EP0701439A1 (en) 1996-03-20
AU7051794A (en) 1994-12-20
TW239077B (xx) 1995-01-21
WO1994027594A2 (en) 1994-12-08
JPH08511006A (ja) 1996-11-19
ZA943857B (en) 1995-02-01

Similar Documents

Publication Publication Date Title
Balzarini et al. 9-(2-Phosphonylmethoxyethyl) adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys
EP1079826B1 (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
OA10198A (en) Stable copper(i) complexes and methods related thereto
De Clercq The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
Touyz et al. Reactive oxygen species in vascular biology: implications in hypertension
US9809616B2 (en) Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
Gluck et al. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations.
AU2005249363A1 (en) Phosphonate analogs of HIV integrase inhibitor compounds
US5637311A (en) Zinc(II) complexes and methods related thereto
Rosowsky et al. Methotrexate analogs. 19. Replacement of the glutamate side-chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity
Sharkey et al. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I
Levinson Inhibition of Viruses, Tumors, and Pathogenic Microorganisms by Isatin β-Thiosemicarbazone and Other Thiosemicarbazones
Al-Jafari et al. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine
Sato et al. Evidence of direct generation of oxygen free radicals from heterocyclic amines by NADPH/cytochrome P‐450 reductase in vitro
WO1996039144A1 (en) Stable copper(i) complexes as active therapeutic substances
Saraswathi et al. Inhibition of glycolysis and respiration of sarcoma-180 cells by echitamine chloride
Sayre et al. Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium‐like substances
Hampton et al. Evidence for the conformation of enzyme-bound adenosine 5'-phosphate. Substrate and inhibitor properties of 8, 5'-cycloadenosine 5'-phosphate with adenylate kinase, adenylate aminohydrolase, adenylosuccinate lyase, and 5'-nucleotidase
Zheng et al. UNC5293, a potent, orally available and highly MERTK-selective inhibitor
Zhang et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs
CHATTOPADHYAYA The chemical synthesis and antiviral properties of an acyclovir-phospholipid conjugate
Hamon et al. Effect of antineoplastic and cytotoxic Mannich bases derived from conjugated styryl ketones on mitochondrial respiration in rat liver cells
Rosowsky et al. Synthesis and in vitro activity of long-chain 5 ‘-O-[(Alkoxycarbonyl) phosphinyl]-3 ‘-azido-3 ‘-deoxythymidines against wild-type and AZT-and foscarnet-resistant strains of HIV-1
Tedde et al. Effects of 2′-deoxycoformycin infusion on mouse adenosine deaminase
Kesel Synthesis of retinoid vitamin A–vitamin B6 conjugate analogues for antiviral chemotherapy